Avience Biomedicals IPO: Strong Listing Expected as GMP Hits 62%
Avience Biomedicals is poised for a high-octane debut on the NSE SME platform this Thursday, fueled by intense investor enthusiasm. Current grey market signals suggest a massive premium, signaling significant potential for listing gains for early investors.
Massive Subscription Numbers Drive Market Hype
The Avience Biomedicals IPO has witnessed extraordinary demand, reflecting deep confidence in the company's business model. The ₹30.24 crore issue, consisting entirely of a fresh issue of 14.54 lakh shares, was oversubscribed a staggering 385.32 times during its three-day bidding window.
The demand was particularly aggressive in the non-institutional investor (NII) segment, which saw a massive 597.23 times subscription. Retail investors also showed intense interest, oversubscribing their portion by 401.36 times, while Qualified Institutional Buyers (QIBs) subscribed 196.77 times. This overwhelming participation across all categories underscores the high liquidity and interest surrounding this SME offering.
Grey Market Premium Signals Strong Debut
Market sentiment appears exceptionally bullish as the company prepares to list at its fixed price of ₹208 per share. According to grey market trends, the shares are commanding a premium (GMP) of approximately 62%.
If these unofficial market signals hold true, Avience Biomedicals could debut at an estimated price of around ₹337. While the grey market premium is a volatile and unofficial indicator that does not guarantee actual listing prices, the current spread suggests that the market is pricing in significant growth expectations for the diagnostic solutions provider.
Robust Financials and Strategic Expansion Plans
Founded in 2024, Avience Biomedicals has quickly established itself in the biotechnology and in-vitro diagnostics (IVD) sectors. The company specializes in manufacturing and exporting molecular diagnostic solutions, including rapid test kits, biochemistry analysers, and medical devices, catering to hospitals and research centres globally.
The company’s financial trajectory appears promising. For FY25, Avience reported a total income of ₹45.97 crore and a net profit of ₹7.23 crore. This momentum continued into the nine-month period ending January 2026, where it posted revenue of ₹41.94 crore and a profit after tax (PAT) of ₹5.74 crore.
A significant portion of the IPO proceeds is earmarked for strategic growth. The company plans to fund a new manufacturing facility at the Medical Device Park under the Yamuna Expressway Industrial Development Authority in Uttar Pradesh. This expansion, alongside meeting working capital requirements, is designed to scale its production capabilities to meet rising global demand.
Key Takeaways
- High Investor Interest: The IPO saw an overall subscription of 385.32 times, led by NIIs at 597.23 times.
- Potential Listing Gains: A grey market premium of 62% suggests an estimated debut price of ₹337 against the issue price of ₹208.
- Growth-Focused Capital Usage: Proceeds will primarily fund a new manufacturing unit in Uttar Pradesh to boost diagnostic solution production.